

Supplementary Table 1. Additional participant characteristics among individuals living with HIV and receiving care at the San Francisco public HIV clinic during the COVID-19 pandemic, by preference phenotype according to latent class group (N=115).

| Characteristic | Total Sample N = 115 n (%) | Flexible Care n = 78 n (%) | One Provider n = 37 n (%) | P-value |
|-----------------------------------|---|---|--|----------------|
| Survey Language | | | | N/A |
| English | 115/115 (100%) | 78/78 (100%) | 37/37 (100%) | |
| Age Category | | | | 0.01 |
| 25-39 | 44 (38%) | 36 (46%) | 8 (22%) | |
| 40-55 | 52 (45%) | 28 (36%) | 24 (64%) | |
| 55+ | 19 (17%) | 14 (18%) | 5 (13%) | |
| Education | | | | 0.54 |
| K-8 | 18 (16%) | 10 (13%) | 8 (22%) | |
| High school/GED | 45 (40%) | 32 (41%) | 13 (35%) | |
| Some college | 38 (33%) | 27 (35%) | 11 (30%) | |
| Completed college | 14 (12%) | 9 (12%) | 5 (13%) | |
| Length of Time with Current Phone | | | | 0.02 |
| < 1 month | 17 (19%) | 13 (25%) | 4 (11%) | |
| 1 - 6 months | 40 (45%) | 27 (51%) | 13 (37%) | |
| 6 - 12 months | 18 (20%) | 10 (19%) | 8 (23%) | |
| > 1 year | 13 (15%) | 3 (6%) | 10 (29%) | |
| Clinic Utilization †† | | | | |
| Scheduled in-person visit | 110 (96%) | 74 (95%) | 36 (97%) | 0.55 |
| Attended in-person visit | 107 (93%) | 73 (93%) | 34 (92%) | 0.74 |
| # of in-person visits: | 7 [3-16] | 8 [3-21] | 6 [3-10] | 0.03 |
| Median [IQR] | | | | |
| Scheduled telehealth visit | 55 (48%) | 27 (35%) | 28 (76%) | <0.01 |
| Attended telehealth visit | 20 (17%) | 5 (6%) | 15 (40%) | <0.01 |
| # of telehealth visits: | 0 [0-0] | 0 [0-0] | 0 [0-1] | <0.01 |
| Median [IQR] | | | | |
| Viral Load Category ‡‡ | | | | 0.34 |
| Undetectable (< 200 copies/mL) | 58 (50%) | 43 (55%) | 15 (41%) | |
| Detectable (> 200 copies/mL) | 44 (38%) | 27 (35%) | 17 (46%) | |
| Missing | 13 (11%) | 8 (10%) | 5 (14%) | |
| CD4 Category §§ | | | | 0.51 |
| < 200 cells/mm ³ | 35 (30%) | 23 (30%) | 12 (32%) | |
| 200 – 349 cells/mm ³ | 17 (15%) | 12 (15%) | 5 (14%) | |
| 350 – 499 cells/mm ³ | 22 (19%) | 18 (23%) | 4 (11%) | |
| > 500 cells/mm ³ | 33 (29%) | 21 (27%) | 12 (32%) | |
| Missing | 8 (7%) | 4 (5%) | 4 (11%) | |

†† Includes medical and social work visits 4 months prior to survey, all visits scheduled or occurred during local SIP ordinances. ‡ ‡ Most recent viral load measurement 6 months prior to survey date. §§ Most recent CD4 cell count 12 months prior to survey date.